Project Grant R01HL184152
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $850,669 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate place-based drivers of health in sickle cell disease pathogenesis. The project will identify and quantify mechanisms linking neighborhood and personal exposures—including crime-related stressors, unhealthy food access, temperature, airborne particulates, and housing conditions—to clinical...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $3.095 million on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of genetic variation's role in congenital heart disease causality and outcomes. The award funds a program project grant structured around four synergistic research projects supported by administrative and computational cores. Project 1 deepens understanding of genetic causality of...
- The National Heart Lung and Blood Institute awarded Icahn School of Medicine at Mount Sinai $763,862 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the metabolic control of immune cell function in atherogenesis. The research examines the role of methylmalonic acid (MMA)—a byproduct of propionyl-CoA catabolism—in macrophage inflammatory processes that drive atherosclerotic cardiovascular disease. Preliminary data show that genetic deficiency of...
- The National Heart, Lung, and Blood Institute awarded the University of Mississippi Medical Center $333,250 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to adapt and pilot-test a home blood pressure monitoring intervention for rural Mississippi. The recipient will modify a validated chronic disease self-management program that combines longitudinal home blood pressure monitoring with a smartphone-delivered virtual agent providing personalized education. The...
- The National Heart, Lung, and Blood Institute awarded $1.175 million to Icahn School of Medicine at Mount Sinai on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate hemogenic mesoderm heterogeneity, regulation, and function in the developing mammalian hematopoietic system. The research, led by Dr. Sturgeon, delineates the molecular and transcriptional mechanisms by which hemogenic mesoderm gives rise to embryonic hematopoietic programs. The work...
- The National Heart, Lung, and Blood Institute awarded New York University $847,163 on August 13, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and implement the Community-to-Clinic Implementation Program to Control Hypertension in Barbershops (CLIP HTN). The award funds a research initiative to test whether community health worker-delivered hypertension screening and linkage services delivered through barbershops improve blood pressure control and linkage to...
- The National Heart Lung and Blood Institute awarded New York University $510,538 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a hybrid effectiveness-implementation study integrating the HEARTS package—a World Health Organization–recommended strategy comprising healthy lifestyle counseling, evidence-based treatment protocols, access to medicines, risk-based care, task-sharing, and systems monitoring—into primary healthcare centers in Nigeria...
- The National Heart Lung and Blood Institute awarded New York University School of Medicine $186,706 for a K23 Career Development Award on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will evaluate multi-level contexts and barriers affecting primary care clinicians' prescribing of remote patient monitoring (RPM) for hypertension management, then design and test an electronic health record-based prescribing workflow (EHR-RPM) to increase RPM...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $908,994 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to test implementation strategies for electronic health record-based interventions to improve hypertension control in primary care settings. The project builds on the recipient's prior NIH-funded REDUCE-BP trial, which enrolled 49,210 patients and 560 primary care providers and demonstrated that multi-component...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $462,000 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct comparative analysis of thrombogenic risk across menopausal stages in women with HIV. The research examines sex-based differences in cardiovascular disease risk among women with HIV, focusing on how immune activation, platelet reactivity, and age-related changes in sex hormones interact to elevate...
The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $672,958 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on task-shifting models for hypertension care in low-resource rural settings. The research project, titled "Task-Shifting at the Doorstep of the People: Strengthening the Hypertension Care Continuum Within Primary Health Care in a Low-Resource Setting," develops and tests COMBINE, a 90-day nurse-led and community health worker–supported screening and treatment program adapted from Ghana's nationwide rural health system. The project addresses the hypertension care gap in rural America—where hypertension prevalence is higher and physician access is limited—by identifying effective, cost-effective, and scalable models that leverage nurses and community health workers in partnership with physicians, consistent with guidelines from the American Heart Association, American Medical Association, and Rural Health Transformation Program. The award period runs through May 31, 2031, with place of performance in New York, New York. This is a Project Grant, a competitive research award evaluated on scientific merit, investigator qualifications, technical adequacy of design, facility resources, budget necessity, and relevance to NHLBI program objectives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $319.1k | 9/3/26 | ||
| Not listed | $353.9k | 8/25/26 |